Literature DB >> 32121554

Diversity of Clinically Relevant Outcomes Resulting from Hypofractionated Radiation in Human Glioma Stem Cells Mirrors Distinct Patterns of Transcriptomic Changes.

Darius Kalasauskas1,2, Maxim Sorokin3,4,5, Bettina Sprang1, Alhassan Elmasri1, Sina Viehweg1, Gabriela Salinas6, Lennart Opitz6, Margret Rave-Fraenk7, Walter Schulz-Schaeffer8, Sven Reiner Kantelhardt2, Alf Giese9, Anton Buzdin3,4,10,11, Ella L Kim1.   

Abstract

Hypofractionated radiotherapy is the mainstay of the current treatment for glioblastoma. However, the efficacy of radiotherapy is hindered by the high degree of radioresistance associated with glioma stem cells comprising a heterogeneous compartment of cell lineages differing in their phenotypic characteristics, molecular signatures, and biological responses to external signals. Reconstruction of radiation responses in glioma stem cells is necessary for understanding the biological and molecular determinants of glioblastoma radioresistance. To date, there is a paucity of information on the longitudinal outcomes of hypofractionated radiation in glioma stem cells. This study addresses long-term outcomes of hypofractionated radiation in human glioma stem cells by using a combinatorial approach integrating parallel assessments of the tumor-propagating capacity, stemness-associated properties, and array-based profiling of gene expression. The study reveals a broad spectrum of changes in the tumor-propagating capacity of glioma stem cells after radiation and finds association with proliferative changes at the onset of differentiation. Evidence is provided that parallel transcriptomic patterns and a cumulative impact of pathways involved in the regulation of apoptosis, neural differentiation, and cell proliferation underly similarities in tumorigenicity changes after radiation.

Entities:  

Keywords:  glioblastoma; glioma stem cells; hypofractionated radiation; radioresistance

Year:  2020        PMID: 32121554     DOI: 10.3390/cancers12030570

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

1.  Next-Generation Grade and Survival Expression Biomarkers of Human Gliomas Based on Algorithmically Reconstructed Molecular Pathways.

Authors:  Marianna A Zolotovskaia; Max A Kovalenko; Victor S Tkachev; Alexander M Simonov; Maxim I Sorokin; Ella Kim; Denis V Kuzmin; Betul Karademir-Yilmaz; Anton A Buzdin
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

2.  DNA repair pathway activation features in follicular and papillary thyroid tumors, interrogated using 95 experimental RNA sequencing profiles.

Authors:  Uliana Vladimirova; Pavel Rumiantsev; Marianna Zolotovskaia; Eugene Albert; Aleksander Abrosimov; Konstantin Slashchuk; Petr Nikiforovich; Olga Chukhacheva; Nurshat Gaifullin; Maria Suntsova; Galina Zakharova; Alexander Glusker; Daniil Nikitin; Andrew Garazha; Xinmin Li; Dmitriy Kamashev; Alexei Drobyshev; Irina Kochergina-Nikitskaya; Maxim Sorokin; Anton Buzdin
Journal:  Heliyon       Date:  2021-03-13

3.  Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.

Authors:  Daniela Hanisch; Andrea Krumm; Tamara Diehl; Carla M Stork; Mario Dejung; Falk Butter; Ella Kim; Walburgis Brenner; Gerhard Fritz; Thomas G Hofmann; Wynand P Roos
Journal:  Cell Death Dis       Date:  2022-04-01       Impact factor: 8.469

4.  ALDH1A3 Segregated Expression and Nucleus-Associated Proteasomal Degradation Are Common Traits of Glioblastoma Stem Cells.

Authors:  Julian Fauß; Bettina Sprang; Petra Leukel; Clemens Sommer; Teodora Nikolova; Florian Ringel; Ella L Kim
Journal:  Biomedicines       Date:  2021-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.